Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

NIH

Sponsor class

Conditions

Advanced Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography with Contrast
PROCEDURE: Echocardiography Test
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Multigated Acquisition Scan
DRUG: Osimertinib

Sponsor

National Cancer Institute (NCI)